What allergic reactions have been reported with Keytruda (pembrolizumab)?
Keytruda can trigger immune-related adverse effects and, in some cases, true allergic (hypersensitivity) reactions. Reported reactions can range from mild symptoms (like rash) to more serious reactions such as anaphylaxis or severe infusion reactions. These events are usually monitored during dosing and shortly after, because some reactions can occur during or after an infusion.
What symptoms should patients or caregivers watch for?
During a Keytruda infusion or after receiving it, watch for signs that could signal an allergic reaction, including:
- Skin changes such as hives, itching, or widespread rash
- Swelling of the face, lips, tongue, or throat
- Trouble breathing, wheezing, or persistent cough
- Dizziness, fainting, or feeling like the heart is racing
- Severe chills, fever, or sudden worsening during/soon after infusion
If symptoms suggest anaphylaxis (for example, breathing difficulty plus swelling, hives, or faintness), emergency care is needed immediately.
Can Keytruda cause a rash that isn’t an allergy?
Yes. Keytruda can also cause immune-related skin reactions that may look similar to an allergic rash, such as drug rashes or other immune-mediated skin problems. The practical difference is that immune-related rashes can be part of the treatment’s immune activation, while allergic reactions (hypersensitivity) are caused by the body’s immediate allergic response mechanism. Clinicians still treat both cautiously because severe skin reactions can be dangerous regardless of cause.
How are allergic reactions to Keytruda treated during an infusion?
Treatment depends on severity. Common clinical approaches include:
- Stopping or slowing the infusion immediately if a reaction occurs
- Giving emergency medications for severe reactions (such as epinephrine, antihistamines, or corticosteroids), when appropriate
- Providing supportive care for breathing or blood pressure changes
- Using later dose adjustments or discontinuation if the reaction is severe
Because this is cancer immunotherapy, clinicians typically follow a risk-severity plan for restarting, delaying, or permanently stopping Keytruda if reactions recur or are serious.
What happens if someone has an allergy to Keytruda—can they keep taking it?
If a patient experiences a mild reaction, the care team may still consider continued treatment with precautions. If the reaction is moderate to severe, clinicians often withhold further dosing or permanently discontinue Keytruda, depending on the type and grade of the event. The decision is individualized based on whether the reaction looks like an immediate hypersensitivity reaction versus an immune-related adverse event, and on how severe it was.
How fast after dosing can allergic reactions happen?
Allergic or infusion-related reactions can occur during the infusion or soon after. Immune-related reactions can also develop over days to weeks, so any new rash, breathing symptoms, swelling, or systemic symptoms should be reported promptly to the oncology team.
Does having allergies or asthma increase the risk?
A history of drug allergies can increase concern for future hypersensitivity reactions, but risk varies by person. Asthma and other allergic conditions are commonly considered when planning infusions and monitoring, especially if prior treatments triggered similar symptoms. Patients should tell the oncology team about:
- Previous reactions to pembrolizumab or other immune checkpoint inhibitors
- Prior infusion reactions to monoclonal antibodies
- Severe allergies, anaphylaxis history, or uncontrolled asthma
When should patients contact their oncology team urgently?
Patients should seek urgent medical advice for any of the following after Keytruda:
- Breathing trouble, wheezing, or throat tightness
- Swelling of face/lips/tongue
- Hives that spread or don’t resolve quickly
- Fainting, severe dizziness, or signs of low blood pressure
- Rapidly worsening rash or painful skin
For emergency symptoms (especially breathing problems or fainting), use emergency services rather than waiting for clinic guidance.
Are there alternatives if Keytruda can’t be continued?
If Keytruda is stopped due to a severe reaction, clinicians may switch to another cancer therapy depending on the specific cancer type, stage, and available treatment options. The replacement regimen is selected based on the disease characteristics and the patient’s overall risk profile.
Sources
No source links were provided with your question. If you want, tell me which Keytruda labeling (U.S./EU) your clinic uses or share the reaction details you’re concerned about (timing, symptoms, severity), and I can align the answer to the specific Keytruda prescribing information and major safety references.